Membership in the Alliance to Zero fits perfectly with our sustainability strategy, which includes striving for climate neutrality at all our sites worldwide by 2030.Dirk Lambrecht, CEO
In order to develop solutions that will have broad acceptance and a true positive impact on the pharmaceutical industry, the alliance recognises the need for deep and proactive collaboration across traditional company boundaries. The founding companies of the alliance represent key parts of the pharma supply chain, including component suppliers, machine suppliers and assembly/manufacturing service providers, as well as those involved in primary packaging to final device assembly and even collection after use.
The formation of this alliance is the first step in a challenging but urgent journey that our member organisations have committed themselves to. Enabling the launch of net zero pharmaceutical products in regulated markets will require companies like ours to transform our operations, products, services, logistics, innovations and investments. Our combined effort and our shared responsibility to ensure a real and lasting change is at the heart of the Alliance’s mission.Sebastian Gerner, president of the Alliance to Zero
The alliance has begun development of a roadmap describing what a net zero emission concept for pharmaceutical manufacturing and supply chain would look like and the steps necessary to achieve it. This foundational work also includes agreement on harmonized language and principles for the assessment and control of the total emission footprint for the final pharmaceutical products, as well as the company-specific responsibilities.